Vivos Therapeutics Stock Market Value
| VVOS Stock | USD 1.67 0.04 2.34% |
| Symbol | Vivos |
Is there potential for Health Care Equipment & Supplies market expansion? Will Vivos introduce new products? Factors like these will boost the valuation of Vivos Therapeutics. If investors know Vivos will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Vivos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.77) | Revenue Per Share | Quarterly Revenue Growth 0.757 | Return On Assets | Return On Equity |
Investors evaluate Vivos Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Vivos Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Vivos Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Vivos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vivos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Vivos Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Vivos Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Vivos Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Vivos Therapeutics.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Vivos Therapeutics on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Vivos Therapeutics or generate 0.0% return on investment in Vivos Therapeutics over 90 days. Vivos Therapeutics is related to or competes with Allurion Technologies, EnVVeno Medical, Co Diagnostics, Aethlon Medical, Envoy Medical, Adagio Medical, and OSR Holdings. Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients ... More
Vivos Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Vivos Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Vivos Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 31.84 | |||
| Value At Risk | (6.17) | |||
| Potential Upside | 7.18 |
Vivos Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vivos Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Vivos Therapeutics' standard deviation. In reality, there are many statistical measures that can use Vivos Therapeutics historical prices to predict the future Vivos Therapeutics' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.46) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (0.39) |
Vivos Therapeutics February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.38) | |||
| Mean Deviation | 3.38 | |||
| Coefficient Of Variation | (1,293) | |||
| Standard Deviation | 4.95 | |||
| Variance | 24.49 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.46) | |||
| Total Risk Alpha | (0.82) | |||
| Treynor Ratio | (0.39) | |||
| Maximum Drawdown | 31.84 | |||
| Value At Risk | (6.17) | |||
| Potential Upside | 7.18 | |||
| Skewness | 2.12 | |||
| Kurtosis | 9.24 |
Vivos Therapeutics Backtested Returns
Vivos Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0982, which indicates the firm had a -0.0982 % return per unit of risk over the last 3 months. Vivos Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Vivos Therapeutics' Coefficient Of Variation of (1,293), risk adjusted performance of (0.05), and Variance of 24.49 to confirm the risk estimate we provide. The entity has a beta of 1.02, which indicates a somewhat significant risk relative to the market. Vivos Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Vivos Therapeutics is expected to follow. At this point, Vivos Therapeutics has a negative expected return of -0.48%. Please make sure to validate Vivos Therapeutics' potential upside and day median price , to decide if Vivos Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.62 |
Good predictability
Vivos Therapeutics has good predictability. Overlapping area represents the amount of predictability between Vivos Therapeutics time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Vivos Therapeutics price movement. The serial correlation of 0.62 indicates that roughly 62.0% of current Vivos Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.62 | |
| Spearman Rank Test | 0.77 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.